Gasjens T.,Briining D.,Taeger D. .2020 .Cancer risks of firefighters: A systematic review and meta-analysis of secular trends and region-specific differences. Int. Arch. Occup., : .
Environ . .. , 93 : 839-852.
Minotti G,Menna P.,Cairo G.,Gianni L. .2004 .AnthrMaoleccularyadcvanlcesianndpeharmsaco:logic developments in antitumor activity and cardiotoxicity. , : .
Pharmacol. Rev. . .. , 56 : 185-229.
Brunton L,Parker K. .2005 .Goodman and Gilman's The Pharmacological Basis of Therapeutics.. , : .
Pages .1984 .McGraw Hill Professional. , 9780071608916 : .
Luu A.Z,Chowdhury B.,Al-Omran M.,Teoh H.,Hess D.A.,Verma S. .2018 .Role of endothelium in doxorubicin-induced cardiomyopathy. JACC: Basic Transl. Sci,, 3 : 861-870.
Kip AE,Rosing H.,Beijnen J.H.,Dorlo T.P.C. .2017 .Volumetric absorptive microsampling (VAMS) as an alternto acotnvientvioenal dried blood spotsin the quantification of miltefosine in dried blood samples. , : .
Pharm J.,Fillet M.,M. M.,Mandrioli R.,Mercolini L,G L .2012 .European Medicines Agency guideline on bioanalytical method validation: What more is there to say? Bioanalysis,. Anal. Chim. Acta, 4 : 865-868.
Babaei N.,M.U. Salamci N.,S N.,CS. Ang P.,Wong N.S.,Lee EJD.,Chowbay B. .2008 .CBR7 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci., 99 : 2045-2054.
Gonzalez-Covarrubias V.,Zhang J.,Kalabus J.L.,Relling M.V.,Blanco J.G.,Dipiro J.T.,Schwinghammer T.L.,Dipiro C.V.,Handbook Pharmacotherapy,Blanco J.G,WM. Leisenring V.M.,Gonzalez-Covarrubias S.M.,Davies S.M.,White C.C.,Kavanagh T.J.,Chem T.J.,M. T.J.,Di L. .2017 .The role of carbonyl reductase 1 in drug discovery and development. Expert Opin. Drug Metab, 13 : 859-870.
Perez EA,Davidson N.E.,S. N.E.,Ewer M.S. .2003 .Congestive heart failure in patients treated with doxorubicin: Aretrospective analysis of three trials. Cancer, 97 : 2869-2879.